News - Page 3 of 40 - AMRF

“Systematic Functional Annotation of Somatic Mutations in Cancer.”

Ng, P. K., J. Li, K. J. Jeong, S. Shao, H. Chen, Y. H. Tsang, S. Sengupta, Z. Wang, V. H. Bhavana, R. Tran, S. Soewito, D. C. Minussi, D. Moreno, K. Kong, T. Dogruluk, H. Lu, J. Gao, C. Tokheim, D. C. Zhou, A. M. Johnson, J. Zeng, C. K. M. Ip, Z. Ju, M. Wester, S. Yu, Y. Li, C. P. Vellano, N. Schultz, R. Karchin, L. Ding, Y. Lu, L. W. T. Cheung, K. Chen, K. R. Shaw, F. Meric-Bernstam, K. L. Scott, S. Yi, N. Sahni, H. Liang and G. B. Mills
Cancer Cell, 2018.

“Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.”

Sun, C., Y. Fang, J. Yin, J. Chen, Z. Ju, D. Zhang, X. Chen, C. P. Vellano, K. J. Jeong, P. K. Ng, A. K. B. Eterovic, N. H. Bhola, Y. Lu, S. N. Westin, J. R. Grandis, S. Y. Lin, K. L. Scott, G. Peng, J. Brugge and G. B. Mills
Sci Transl Med, 2017.

“Neomorphic mutations create therapeutic challenges in cancer.”

Takiar, V., C. K. Ip, M. Gao, G. B. Mills and L. W. Cheung
Oncogene, 2017.

“Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.”

Topper, M. J., M. Vaz, K. B. Chiappinelli, C. E. DeStefano Shields, N. Niknafs, R. C. Yen, A. Wenzel, J. Hicks, M. Ballew, M. Stone, P. T. Tran, C. A. Zahnow, M. D. Hellmann, V. Anagnostou, P. L. Strissel, R. Strick, V. E. Velculescu and S. B. Baylin
Cell, 2017.

“Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations.”

Vaz, M., S. Y. Hwang, I. Kagiampakis, J. Phallen, A. Patil, H. M. O'Hagan, L. Murphy, C. A. Zahnow, E. Gabrielson, V. E. Velculescu, H. P. Easwaran and S. B. Baylin
Cancer Cell, 2017.

“Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.”

Zervantonakis, I. K., C. Iavarone, H. Y. Chen, L. M. Selfors, S. Palakurthi, J. F. Liu, R. Drapkin, U. Matulonis, J. D. Leverson, D. Sampath, G. B. Mills and J. S. Brugge
Nat Commun, 2017.

“A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2′-Deoxycytidine.”

Leadem, B. R., I. Kagiampakis, C. Wilson, T. K. Cheung, D. Arnott, P. Trojer, M. Classon, H. Easwaran and S. B. Baylin
Cancer Res, 2017.

“Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas.”

Li, J., R. Akbani, W. Zhao, Y. Lu, J. N. Weinstein, G. B. Mills and H. Liang
Cancer Res, 2017.

“Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.”

Li, J., W. Zhao, R. Akbani, W. Liu, Z. Ju, S. Ling, C. P. Vellano, P. Roebuck, Q. Yu, A. K. Eterovic, L. A. Byers, M. A. Davies, W. Deng, Y. N. Gopal, G. Chen, E. M. von Euw, D. Slamon, D. Conklin, J. V. Heymach, A. F. Gazdar, J. D. Minna, J. N. Myers, Y. Lu, G. B. Mills and H. Liang
Cancer Cell, 2017.

“Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.”

Liu, J. F., S. Palakurthi, Q. Zeng, S. Zhou, E. Ivanova, W. Huang, I. K. Zervantonakis, L. M. Selfors, Y. Shen, C. C. Pritchard, M. Zheng, V. Adleff, E. Papp, H. Piao, M. Novak, S. Fotheringham, G. M. Wulf, J. English, P. T. Kirschmeier, V. E. Velculescu, C. Paweletz, G. B. Mills, D. M. Livingston, J. S. Brugge, U. A. Matulonis and R. Drapkin
Clin Cancer Res, 2017.

“Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.”

Matulonis, U. A., G. M. Wulf, W. T. Barry, M. Birrer, S. N. Westin, S. Farooq, K. M. Bell-McGuinn, E. Obermayer, C. Whalen, T. Spagnoletti, W. Luo, H. Liu, R. C. Hok, C. Aghajanian, D. B. Solit, G. B. Mills, B. S. Taylor, H. Won, M. F. Berger, S. Palakurthi, J. Liu, L. C. Cantley and E. Winer
Ann Oncol, 2017.

“Direct detection of early-stage cancers using circulating tumor DNA”

Phallen, J., M. Sausen, V. Adleff, A. Leal, C. Hruban, J. White, V. Anagnostou, J. Fiksel, S. Cristiano, E. Papp, S. Speir, T. Reinert, M. W. Orntoft, B. D. Woodward, D. Murphy, S. Parpart-Li, D. Riley, M. Nesselbush, N. Sengamalay, A. Georgiadis, Q. K. Li, M. R. Madsen, F. V. Mortensen, J. Huiskens, C. Punt, N. van Grieken, R. Fijneman, G. Meijer, H. Husain, R. B. Scharpf, L. A. Diaz, Jr., S. Jones, S. Angiuoli, T. Orntoft, H. J. Nielsen, C. L. Andersen and V. E. Velculescu
Sci Transl Med, 2017.

“Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.”

Stone, M. L., K. B. Chiappinelli, H. Li, L. M. Murphy, M. E. Travers, M. J. Topper, D. Mathios, M. Lim, I. M. Shih, T. L. Wang, C. F. Hung, V. Bhargava, K. R. Wiehagen, G. S. Cowley, K. E. Bachman, R. Strick, P. L. Strissel, S. B. Baylin and C. A. Zahnow
Proc Natl Acad Sci U S A, 2017.

“Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.”

Wang, S., A. Blois, T. El Rayes, J. F. Liu, M. S. Hirsch, K. Gravdal, S. Palakurthi, D. R. Bielenberg, L. A. Akslen, R. Drapkin, V. Mittal and R. S. Watnick
Sci Transl Med, 2016.

“Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.”

Anagnostou, V., K. N. Smith, P. M. Forde, N. Niknafs, R. Bhattacharya, J. White, T. Zhang, V. Adleff, J. Phallen, N. Wali, C. Hruban, V. B. Guthrie, K. Rodgers, J. Naidoo, H. Kang, W. Sharfman, C. Georgiades, F. Verde, P. Illei, Q. K. Li, E. Gabrielson, M. V. Brock, C. A. Zahnow, S. B. Baylin, R. B. Scharpf, J. R. Brahmer, R. Karchin, D. M. Pardoll and V. E. Velculescu
Cancer Discov, 2017.

“Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.”

Au-Yeung, G., F. Lang, W. J. Azar, C. Mitchell, K. E. Jarman, K. Lackovic, D. Aziz, C. Cullinane, R. B. Pearson, L. Mileshkin, D. Rischin, A. M. Karst, R. Drapkin, D. Etemadmoghadam and D. D. Bowtell
Clin Cancer Res, 2017.